Clinical data of study patients
| . | Δ thrombus score ≥4 (n = 26) . | Δ thrombus score <4 (n = 22) . |
|---|---|---|
| Patient characteristics | ||
| Male (%) | 46.2% | 45.5% |
| Age (years ± SD) | 68 (±9) | 68 (±11) |
| Current smoker (%) | 15.4% | 13.6% |
| Body mass index (±SD) | 28.5 (±2) | 31.7 (±2) |
| Immobilization/surgery (%) | 15.4% | 18.2% |
| Malignancy (%) | 23.1% | 31.8% |
| Thrombophilia (%) | 0% | 4.5% |
| Previous VTE (%) | 42.3% | 36.4% |
| PTS 12 mo after diagnosis (%) | 16.7% | 50%† |
| Median Villalta score (score; percentile 25/75) | 2.5 (2.0/4.0) | 4.5 (2.0/7.0) |
| Treatments | ||
| Duration of anticoagulation (%) | ||
| 3 to 6 mo | 0% | 9.1% |
| 6 to 12 mo | 15.4% | 22.7% |
| >12 mo | 84.6% | 68.2% |
| Vitamin K antagonists (%)* | 69.2% | 72.7% |
| Therapeutic dosage of low molecular weight heparin (%)* | 26.9% | 27.3% |
| Dabigatran (%)* | 3.9% | 0% |
| D-Dimer and sPECAM-1 | ||
| Median D-Dimer baseline (μg/mL; percentile 25/75) | 4.5 (3.1/11.0) | 3.3 (2.1/4.4) |
| Median D-Dimer d 28 (±3) (μg/mL; percentile 25/75) | 1.2 (0.7/1.5) | 0.7 (0.5/1.5) |
| Median sPECAM-1 baseline (ng/mL; percentile 25/75) | 71.54 (51.05/81.04) | 92.50 (87.73/103.36) ‡ |
| Median sPECAM-1 d 28 (±3) (ng/mL; percentile 25/75) | 71.96 (57.22/87.03) | 90.07 (73.02/102.62)† |
| Thrombus burden | ||
| Mean thrombus score baseline (±SD) | 16.7 (±9.1) | 10.5 (±2.0) |
| Mean thrombus score d 28 (±3) (±SD) | 10.0 (±9.1) | 10.3 (±2.5) |
| Mean Δ thrombus score (±SD) | 6.7 (±2.5) | .3 (±2.4) ‡ |
| Proximal segment baseline (%) | ||
| Popliteal vein | 11.5% | 9.1% |
| Distal femoral vein | 19.2% | 18.2% |
| Femoral vein (mid-segment) | 30.8% | 36.4% |
| Proximal femoral vein | 30.8% | 36.4% |
| External iliac vein | 7.6% | 0% |
| . | Δ thrombus score ≥4 (n = 26) . | Δ thrombus score <4 (n = 22) . |
|---|---|---|
| Patient characteristics | ||
| Male (%) | 46.2% | 45.5% |
| Age (years ± SD) | 68 (±9) | 68 (±11) |
| Current smoker (%) | 15.4% | 13.6% |
| Body mass index (±SD) | 28.5 (±2) | 31.7 (±2) |
| Immobilization/surgery (%) | 15.4% | 18.2% |
| Malignancy (%) | 23.1% | 31.8% |
| Thrombophilia (%) | 0% | 4.5% |
| Previous VTE (%) | 42.3% | 36.4% |
| PTS 12 mo after diagnosis (%) | 16.7% | 50%† |
| Median Villalta score (score; percentile 25/75) | 2.5 (2.0/4.0) | 4.5 (2.0/7.0) |
| Treatments | ||
| Duration of anticoagulation (%) | ||
| 3 to 6 mo | 0% | 9.1% |
| 6 to 12 mo | 15.4% | 22.7% |
| >12 mo | 84.6% | 68.2% |
| Vitamin K antagonists (%)* | 69.2% | 72.7% |
| Therapeutic dosage of low molecular weight heparin (%)* | 26.9% | 27.3% |
| Dabigatran (%)* | 3.9% | 0% |
| D-Dimer and sPECAM-1 | ||
| Median D-Dimer baseline (μg/mL; percentile 25/75) | 4.5 (3.1/11.0) | 3.3 (2.1/4.4) |
| Median D-Dimer d 28 (±3) (μg/mL; percentile 25/75) | 1.2 (0.7/1.5) | 0.7 (0.5/1.5) |
| Median sPECAM-1 baseline (ng/mL; percentile 25/75) | 71.54 (51.05/81.04) | 92.50 (87.73/103.36) ‡ |
| Median sPECAM-1 d 28 (±3) (ng/mL; percentile 25/75) | 71.96 (57.22/87.03) | 90.07 (73.02/102.62)† |
| Thrombus burden | ||
| Mean thrombus score baseline (±SD) | 16.7 (±9.1) | 10.5 (±2.0) |
| Mean thrombus score d 28 (±3) (±SD) | 10.0 (±9.1) | 10.3 (±2.5) |
| Mean Δ thrombus score (±SD) | 6.7 (±2.5) | .3 (±2.4) ‡ |
| Proximal segment baseline (%) | ||
| Popliteal vein | 11.5% | 9.1% |
| Distal femoral vein | 19.2% | 18.2% |
| Femoral vein (mid-segment) | 30.8% | 36.4% |
| Proximal femoral vein | 30.8% | 36.4% |
| External iliac vein | 7.6% | 0% |
Patient characteristics, treatments, laboratory findings, and thrombus burden of patients with normal (Δ thrombus score ≥4) and delayed thrombus resolution (Δ thrombus score <4) at baseline, after 28 (±3) days and 12 (±0.5) months after DVT diagnosis are shown.
SD, standard deviation.
Pharmacological substance was evaluated 28 (±3) d after diagnosis.
P < .05.
P < .01.